Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series-Reference-Cited by-同舟云学术

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

Published:2016-10-06 Issue:11 Volume:115 Page:1280-1284
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Carlino Matteo S,Vanella Vito,Girgis Christina,Giannarelli Diana,Guminski Alex,Festino Lucia,Kefford Richard F,Menzies Alexander M,Long Georgina V,Ascierto Paolo A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016321.pdf

Reference21 articles.

1. Beda M, Basso U, Ghiotto C, Monfardini S (2007) When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? Tumori 93 (5): 491–492.

2. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25 (9): 1107–1113.

3. Carlino MS, Kwan V, Miller DK, Saunders CA, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, Long GV (2014) New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol 33: e52–e56.

4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (26): 2507–2516.

5. Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J (2012) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 23 (7): 1788–1795.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition;Neuro-Oncology;2024-05-14

2. Systemic Treatment of Melanoma;Rook's Textbook of Dermatology;2024-03-19

3. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes;European Journal of Cancer;2023-01

4. A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in <b><i>BRAF</i></b> V600E-Mutated Metastatic Melanoma;Case Reports in Oncology;2022-05-30

5. Targeted therapy for advanced cutaneous melanoma;Oncology in Clinical Practice;2022-02-22